EphA2/CD10/Bcl-6/MUM1 contributes to subclassification of diffuse large B cell lymphoma

Journal of International Translational Medicine

Jinghua Wang¹  Xiaoxiang Guan¹  Qian Sun²  Haijin Fu²  Xiaoyin Huang²  Jiandong Wang² 

[1] Department of Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, 210002, China;Department of Oncology, School of Medicine, Nanjing University, Nanjing, Jiangsu, 211102, China;

关键词: diffuse large B-cell lymphoma;    EphA2;    CD10;    Bcl-6;    MUM-1;    stage;    international prognostic index;    phenotype;    prognosis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Objective: To investigate the clinical and prognostic significance of EphA2 expression in diffuse large B-cell lymphoma (DLBCL). Methods: Immunohistochemistry for EphA2/CD10/Bcl-6/MUM-1 was performed on tissue sections from 51 patients diagnosed with DLBCL, and its correlation with clinicopathologic variables of patients was assessed using Pearson’s χ2 test or Fisher’s exact test when necessary. The survival was analyzed by Kaplan-Meier method. Results: High expression of EphA2 was detected in patients of lower clinical stage (P ＝ 0.001), better international prognostic index (IPI) score (P ＝ 0.020) and germinal center B-cell (GCB) phenotype (P ＝ 0.000). It was also correlated with the expression of CD10 (P ＝ 0.001) and MUM-1 (P ＝ 0.001). Conclusion: EphA2/CD10/MUM1 might contribute to sub-classification of DLBCL.

【 授权许可】

Unknown